Découvrez l'article du mois de janvier des Archives of Cardiovascular Diseases, la revue scientifique en anglais de la SFC :
Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France: insights from the ODYSSEY APPRISE study
Patrick Henry, Bertrand Cariou, Michel Farnier, Sarah L. Lakhdari, Bruno Detournaye
Highlights
• Ancillary analysis of French patients enrolled in ODYSSEY APPRISE.
• Trial conducted to determine lipid-lowering efficacy and safety of alirocumab.
• Real-life setting: patients at high cardiovascular risk with hypercholesterolaemia.
• Statins and ezetimibe are the first and second-line therapies.
• These therapies are used even less in France than in other countries.
• Alirocumab was well tolerated, safe and highly effective at reducing LDL-C.
• This supports PCSK9 use to manage hypercholesterolaemia in high-risk CV patients
Keywords
• Hypercholesterolaemia
• Cardiovascular risk
• PCSK9 inhibitor
• Real-life study
• France